Insider Trading activities of Isis Pharmaceuticals Inc insiders. , Part 3

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Isis Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Isis Pharmaceuticals Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Isis Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is IONS. The reporting company's CIK number is 874015.
The total value of stock buying since 2005 is $90,940.
The total value of stock sales since 2005 is $143,411,749.
The total value of stock option exercises since 2005 is $46,743,600.



Table 2. Detailed insider stock purchases, sales, and option exercises of Isis Pharmaceuticals Inc insiders (IONS) , Part 3
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2014-08-11 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 700 10.29 7,202
2014-08-01 Crooke Stanley T (Chairman, President and CEO) Sale 16,000 30.52 488,400
2014-08-01 Crooke Stanley T (Chairman, President and CEO) Option Ex 16,000 12.87 205,920
2014-07-31 Monia Brett P (SVP, Antisense Drug Discovery) Sale 79 31.50 2,488
2014-07-02 Geary Richard S (SVP, Development) Sale 164 35.95 5,895
2014-07-02 Klein Joseph Iii (Director) Option Ex 313 .00 0
2014-07-02 Muto Frederick T (Director) Option Ex 313 .00 0
2014-07-02 Berthelsen Spencer R (Director) Option Ex 313 .00 0
2014-07-02 Wender Joseph H (Director) Option Ex 313 .00 0
2014-07-01 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,500 35.33 52,999
2014-07-01 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,500 10.29 15,434
2014-07-01 Castleman Breaux (Director) Option Ex 1,407 .00 0
2014-07-01 Klein Joseph Iii (Director) Option Ex 469 .00 0
2014-07-01 Muto Frederick T (Director) Option Ex 469 .00 0
2014-07-01 Berthelsen Spencer R (Director) Option Ex 469 .00 0
2014-07-01 Wender Joseph H (Director) Option Ex 469 .00 0
2014-07-01 Crooke Stanley T (Chairman and CEO) Sale 17,500 35.56 622,282
2014-07-01 Crooke Stanley T (Chairman and CEO) Option Ex 17,500 13.40 234,552
2014-06-23 Bennett C Frank (SVP, Antisense Research) Sale 11,200 36.76 411,656
2014-06-23 Bennett C Frank (SVP, Antisense Research) Option Ex 11,200 15.38 172,256
2014-06-19 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 700 35.31 24,717
2014-06-19 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 700 9.83 6,882
2014-06-19 Crooke Stanley T (Chairman, President and CEO) Sale 11,000 35.10 386,111
2014-06-19 Crooke Stanley T (Chairman, President and CEO) Option Ex 11,000 14.47 159,170
2014-06-16 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 800 35.20 28,158
2014-06-16 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 800 8.00 6,400
2014-06-10 Crooke Stanley T (Chairman, President and CEO) Sale 11,000 33.45 368,005
2014-06-10 Crooke Stanley T (Chairman, President and CEO) Option Ex 11,000 14.47 159,170
2014-06-02 Muto Frederick T (Director) Sale 10,000 28.59 285,900
2014-06-02 Muto Frederick T (Director) Option Ex 10,000 5.72 57,200
2014-04-17 Berthelsen Spencer R (Director) Option Ex 10,000 5.72 57,200
2014-04-02 Crooke Stanley T (Chairman, President and CEO) Sale 8,800 43.65 384,102
2014-04-02 Crooke Stanley T (Chairman, President and CEO) Option Ex 8,800 14.47 127,336
2014-04-01 O'neil Patrick R. (SVP, Legal and General Counsel) Sale 1,500 44.40 66,600
2014-04-01 O'neil Patrick R. (SVP, Legal and General Counsel) Option Ex 1,500 8.00 12,000
2014-03-03 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,500 49.70 74,550
2014-03-03 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,500 10.97 16,455
2014-02-06 Wender Joseph H (Director) Option Ex 5,300 5.72 30,316
2014-02-03 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 1,500 50.45 75,676
2014-02-03 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,500 11.27 16,905
2014-02-03 Wender Joseph H (Director) Sale 4,700 48.78 229,280
2014-02-03 Wender Joseph H (Director) Option Ex 4,700 5.72 26,884
2014-01-30 Parshall B Lynne (COO) Sale 39,510 50.36 1,989,881
2014-01-30 Parshall B Lynne (COO) Option Ex 39,510 8.77 346,502
2014-01-29 Parshall B Lynne (COO) Sale 50,000 48.81 2,440,350
2014-01-29 Parshall B Lynne (COO) Option Ex 50,000 8.66 433,100
2014-01-24 Klein Joseph Iii (Director) Sale 10,313 48.65 501,675
2014-01-24 Klein Joseph Iii (Director) Option Ex 10,313 14.63 150,879
2014-01-22 Geary Richard S (SVP, Development) Sale 22,200 50.05 1,111,021
2014-01-22 Geary Richard S (SVP, Development) Option Ex 22,200 10.97 243,534
2014-01-22 Wender Joseph H (Director) Sale 10,000 50.98 509,799
2014-01-16 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 577 47.08 27,165
2014-01-16 Monia Brett P (SVP, Antisense Drug Discovery) Sale 821 47.08 38,652
2014-01-16 Geary Richard S (SVP, Development) Sale 829 47.08 39,030
2014-01-16 Hougen Elizabeth L (SVP, Finance & CFO) Sale 577 47.08 27,165
2014-01-16 Bennett C Frank (SVP, Antisense Research) Sale 804 47.08 37,853
2014-01-16 Parshall B Lynne (COO & Secretary) Sale 1,641 47.08 77,261
2014-01-16 Crooke Stanley T (Chairman and CEO) Sale 3,527 47.08 166,054
2014-01-15 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 1,509 .00 0
2014-01-15 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 2,151 .00 0
2014-01-15 Geary Richard S (SVP, Development) Option Ex 2,174 .00 0
2014-01-15 Hougen Elizabeth L (SVP, Finance & CFO) Option Ex 1,509 .00 0
2014-01-15 Bennett C Frank (SVP, Antisense Research) Option Ex 2,110 .00 0
2014-01-15 Parshall B Lynne (COO & Secretary) Option Ex 4,310 .00 0
2014-01-15 Crooke Stanley T (Chairman and CEO) Option Ex 9,260 .00 0
2014-01-08 Geary Richard S (SVP, Development) Sale 7,600 42.02 319,352
2014-01-08 Geary Richard S (SVP, Development) Option Ex 7,600 10.29 78,204
2014-01-08 Crooke Stanley T (Chairman, President and CEO) Sale 12,500 40.05 500,650
2014-01-08 Crooke Stanley T (Chairman, President and CEO) Option Ex 12,500 14.47 180,875
2014-01-06 Geary Richard S (SVP, Development) Sale 7,400 38.83 287,364
2014-01-06 Geary Richard S (SVP, Development) Option Ex 7,400 11.27 83,398
2014-01-02 Monia Brett P (SVP, Antisense Drug Discovery) Sale 362 39.25 14,209
2014-01-02 Crooke Stanley T (Chairman, President and CEO) Sale 31,500 39.50 1,244,313
2014-01-02 Crooke Stanley T (Chairman, President and CEO) Option Ex 31,500 14.47 455,805
2013-12-26 Parshall B Lynne (COO) Sale 37,811 40.91 1,546,772
2013-12-26 Parshall B Lynne (COO) Option Ex 37,811 11.27 426,129
2013-12-24 Parshall B Lynne (COO & Secretary) Sale 20,000 41.00 819,920
2013-12-24 Parshall B Lynne (COO & Secretary) Option Ex 20,000 11.27 225,400
2013-12-23 Parshall B Lynne (COO & Secretary) Sale 50,000 41.68 2,084,049
2013-12-23 Parshall B Lynne (COO & Secretary) Option Ex 50,000 12.87 643,500
2013-12-20 Wender Joseph H (Director) Sale 10,000 40.01 400,130
2013-12-19 Wender Joseph H (Director) Sale 9,731 39.13 380,812
2013-12-19 Wender Joseph H (Director) Option Ex 15,000 16.32 244,800
2013-12-05 Bennett C Frank (SVP, Antisense Research) Sale 10,000 39.92 399,200
2013-12-05 Bennett C Frank (SVP, Antisense Research) Option Ex 10,000 15.38 153,800
2013-11-26 Wender Joseph H (Director) Sale 10,000 36.63 366,340
2013-11-25 Klein Joseph Iii (Director) Sale 6,000 36.86 221,154
2013-09-20 Monia Brett P (SVP, Antisense Drug Discovery) Sale 18,281 35.89 656,105
2013-09-20 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 18,281 11.27 206,026
2013-09-20 Parshall B Lynne (COO & Secretary) Sale 40,000 35.90 1,435,920
2013-09-20 Parshall B Lynne (COO & Secretary) Option Ex 40,000 14.93 597,000
2013-09-20 Crooke Stanley T (Chairman and CEO) Sale 8,740 35.90 313,748
2013-09-20 Crooke Stanley T (Chairman and CEO) Option Ex 8,740 11.12 97,188
2013-09-19 Monia Brett P (SVP, Antisense Drug Discovery) Sale 50,000 33.47 1,673,600
2013-09-19 Monia Brett P (SVP, Antisense Drug Discovery) Option Ex 50,000 14.30 715,200
2013-09-19 Bennett C Frank (SVP, Antisense Research) Sale 10,000 35.02 350,200
2013-09-19 Bennett C Frank (SVP, Antisense Research) Option Ex 10,000 15.38 153,800
2013-09-19 Parshall B Lynne (COO & Secretary) Sale 50,000 35.07 1,753,600
2013-09-19 Parshall B Lynne (COO & Secretary) Option Ex 50,000 15.91 795,750
2013-09-19 Crooke Stanley T (Chairman and CEO) Sale 50,000 35.07 1,753,600
2013-09-19 Crooke Stanley T (Chairman and CEO) Option Ex 50,000 11.12 556,000
2013-09-11 Parshall B Lynne (COO) Sale 3,505 31.18 109,289
2013-09-11 Parshall B Lynne (COO) Option Ex 1,520 15.38 23,377
2013-09-11 Crooke Stanley T (COO, President) Sale 20,000 31.18 623,620
2013-09-10 Parshall B Lynne (COO) Sale 30,000 31.65 949,440
2013-09-10 Parshall B Lynne (COO) Option Ex 30,000 15.38 461,400
2013-09-10 Crooke Stanley T (COO, President) Sale 30,000 31.65 949,440
2013-09-09 Bennett C Frank (SVP, Antisense Research) Sale 10,000 30.23 302,250
2013-09-09 Bennett C Frank (SVP, Antisense Research) Option Ex 10,000 15.38 153,800
2013-09-09 Parshall B Lynne (COO) Sale 30,000 30.41 912,450
2013-09-09 Parshall B Lynne (COO) Option Ex 30,000 15.38 461,400
2013-09-09 Crooke Stanley T (COO, President) Sale 26,615 30.41 809,495
2013-09-09 Crooke Stanley T (COO, President) Option Ex 26,615 11.12 295,958
2013-09-04 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 2,500 26.96 67,400
2013-09-04 O'neil Patrick R. (SVP, Legal & General Counsel) Option Ex 2,500 12.49 31,230
2013-08-26 Monia Brett P (SVP, Antisense Drug Discovery) Sale 2,909 25.58 74,403
2013-08-09 Klein Joseph Iii (Director) Sale 18,750 28.22 529,181
2013-08-09 Klein Joseph Iii (Director) Option Ex 18,750 11.57 216,937
2013-07-23 Crooke Stanley T (COO, President) Sale 11,500 30.00 345,000
2013-07-23 Crooke Stanley T (COO, President) Option Ex 11,500 11.12 127,879
2013-07-22 Crooke Stanley T (Chairman and CEO) Sale 20,000 30.86 617,100
2013-07-22 Crooke Stanley T (Chairman and CEO) Option Ex 20,000 13.96 279,200
2013-07-19 Crooke Stanley T (Chairman and CEO) Sale 22,200 30.82 684,181
2013-07-19 Crooke Stanley T (Chairman and CEO) Option Ex 22,200 15.38 341,436
2013-07-18 Crooke Stanley T (Chairman and CEO) Sale 20,000 30.11 602,220
2013-07-18 Crooke Stanley T (Chairman and CEO) Option Ex 20,000 11.12 222,399
2013-07-17 Crooke Stanley T (Chairman and CEO) Sale 13,300 31.71 421,782
2013-07-17 Crooke Stanley T (Chairman and CEO) Option Ex 13,300 13.56 180,348
2013-07-16 Crooke Stanley T (Chairman and CEO) Sale 6,000 33.31 199,842
2013-07-16 Crooke Stanley T (Chairman and CEO) Option Ex 6,000 11.12 66,720
2013-07-15 Crooke Stanley T (Chairman and CEO) Sale 30,000 33.81 1,014,179
2013-07-15 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 11.12 333,600
2013-07-12 Crooke Stanley T (Chairman and CEO) Sale 30,000 33.14 994,140
2013-07-12 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 12.54 376,200
2013-07-11 Geary Richard S (SVP, Development) Sale 9,000 31.90 287,100
2013-07-11 Geary Richard S (SVP, Development) Option Ex 9,000 11.12 100,080
2013-07-11 Crooke Stanley T (Chairman and CEO) Sale 30,000 32.00 960,090
2013-07-11 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 15.38 461,400
2013-07-10 Crooke Stanley T (Chairman and CEO) Sale 30,000 30.05 901,440
2013-07-10 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 15.38 461,400
2013-07-09 Geary Richard S (SVP, Development) Sale 10,358 30.04 311,185
2013-07-09 Geary Richard S (SVP, Development) Option Ex 10,358 10.29 106,583
2013-07-09 Crooke Stanley T (Chairman and CEO) Sale 30,000 30.04 901,290
2013-07-09 Crooke Stanley T (Chairman and CEO) Option Ex 30,000 15.38 461,400
2013-07-08 Geary Richard S (SVP, Development) Sale 30,000 30.07 902,070
2013-07-08 Geary Richard S (SVP, Development) Option Ex 30,000 10.94 328,290
2013-07-08 Crooke Stanley T (Chairman and CEO) Sale 54,992 25.16 1,383,873
2013-07-08 Crooke Stanley T (Chairman and CEO) Option Ex 5,008 15.38 77,023
2013-07-05 O'neil Patrick R. (SVP, Legal & General Counsel) Sale 277 29.25 8,102
2013-07-05 Geary Richard S (SVP, Development) Sale 25,805 29.82 769,608

Insider trading activities including stock purchases, stock sales, and option exercises of IONS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Isis Pharmaceuticals Inc (symbol IONS, CIK number 874015) see the Securities and Exchange Commission (SEC) website.